Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).

Authors

Sant P. Chawla

Sarcoma Oncology Research Center, Santa Monica, CA

Sant P. Chawla , Gerald Steven Falchook , Melissa Amber Burgess , James Lin Chen , Robin Lewis Jones , Victoria S. Chua , Coya Tapia , Jessica Ainscough , Anthony Hamlett , Melinda S. Merchant , Rashmi Chugh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2020 ASCO Virtual Scientific Program

bookmark_border

A phase Ib/III randomized, double-blind, placebo-controlled study of tazemetostat plus doxorubicin as frontline therapy for patients with advanced epithelioid sarcoma.

First Author: Shiraj Sen

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).

First Author: Makoto Endo

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 3 study (TILVANCE-301) to assess the efficacy and safety of lifileucel, an autologous tumor-infiltrating lymphocyte cell therapy, in combination with pembrolizumab compared with pembrolizumab alone in patients with untreated unresectable or metastatic melanoma.

First Author: Daniel Olson

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS).

First Author: Evan Rosenbaum